T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023
05 Outubro 2023 - 5:05PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, announced today that it will report preliminary financial
results for the third quarter 2023 and business updates after
market close on Thursday, October 12, 2023. Company management will
host a corresponding conference call beginning at 4:30 p.m.
Eastern Time.
Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.t2biosystems.com, on the Investors page in
the Events & Presentations section. To listen to the conference
call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011
(International), passcode 505931, approximately ten to five minutes
prior to the start time.
About T2 BiosystemsT2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, the
T2Biothreat™ Panel, and the T2SARS-CoV-2™ Panel and are powered by
the proprietary T2 Magnetic Resonance (T2MR®) technology. T2
Biosystems has an active pipeline of future products, including the
Acinetobacter baumannii test, the Candida auris test, and T2Lyme™
Panel, as well as next-generation products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers. For more information, please visit
www.t2biosystems.com.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
T2 Biosystems (NASDAQ:TTOO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024